Docosahexaenoic Acid / LDH Cancer Research Results

DHA, Docosahexaenoic Acid: Click to Expand ⟱
Features:

Docosahexaenoic Acid (DHA) = long-chain omega-3 polyunsaturated fatty acid (22:6n-3); major structural lipid of neuronal membranes and retina; dietary sources: fatty fish (salmon, sardine), algae oils; often combined with EPA in supplements.
Primary mechanisms (conceptual rank):
1) Membrane incorporation → alters fluidity, lipid rafts, receptor signaling domains.
2) Pro-resolving lipid mediator precursor (resolvins, protectins, maresins) → inflammation resolution.
3) Mitochondrial modulation → can ↑ lipid-ROS in cancer (pro-ferroptotic bias) yet stabilize neuronal bioenergetics.
4) Synaptic function / neurogenesis support (BDNF-linked, model-dependent).
PK / bioavailability: absorbed with dietary fat; re-esterified into phospholipids; crosses BBB; brain incorporation is gradual (weeks–months); higher RBC-DHA correlates with intake.
In-vitro vs systemic exposure: many cancer studies use ≥25–100 µM free DHA; achievable plasma levels from oral dosing are typically lower and largely esterified, limiting direct comparability.
Clinical evidence status: strong cardiometabolic data; oncology evidence largely preclinical/adjunct; AD/MCI data mixed but mechanistically coherent.

Omega-3 fatty acid found in cold-water fish and some supplements.
– DHA is a major structural component of cell membranes in the brain, retina, and other tissues and plays a critical role in neural function and development.

Role in Cancer

Anti-Inflammatory Effects: – A reduction in chronic inflammation
Modulation of Cell Proliferation and Apoptosis
 –Omega-3 fatty acids appear to influence cell cycle regulation and apoptosis (programmed cell death). By enhancing apoptosis and inhibiting proliferation, these agents may limit the growth of cancer cells.
Alteration of Membrane Composition and Signaling
 –May affect processes such as angiogenesis (formation of new blood vessels), cell adhesion, and metastasis in cancer cells.
Impact on Oxidative Stress
 –Although omega-3 fatty acids are prone to oxidation, their metabolites can have antioxidant properties. Balancing oxidation and antioxidant defenses is important in preventing oxidative stress—a known contributor to DNA damage and cancer development.
Anti-Angiogenic Effects
 – Some studies have shown that EPA and DHA can inhibit angiogenesis.

Docosahexaenoic Acid (DHA) — Cancer-Relevant Pathways

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Lipid peroxidation / Ferroptosis axis ↑ (pro-ferroptotic bias; dose-dependent) ↔ / mild ↑ (buffered) P→R PUFA enrichment → lipid-ROS susceptibility DHA increases membrane PUFA content; tumors with weak GPX4 defenses more vulnerable (model-dependent).
2 ROS tone ↑ (high concentration only) ↔ P→R Oxidative stress induction Free DHA oxidation can elevate ROS in cancer; physiologic dosing less pronounced.
3 Inflammation (NF-κB / COX-2) ↓ ↓ R→G Anti-inflammatory / pro-resolving Via resolvins/protectins; may reduce tumor-promoting inflammation.
4 Membrane signaling / lipid rafts ↓ oncogenic signaling (context-dependent) Modulates receptor clustering R→G Alters RTK / Akt pathway localization Changes raft composition; can dampen EGFR/PI3K signaling (model-dependent).
5 HIF-1α / hypoxia signaling ↓ (model-dependent) ↔ G Reduced hypoxic adaptation Reported in some solid tumor models; not universal.
6 NRF2 axis ↔ / ↑ (adaptive) ↑ (protective) G Antioxidant adaptation Lipid peroxidation may secondarily activate NRF2; can limit ferroptosis in resistant tumors.
7 Ca²⁺ signaling / ER stress ↑ (high concentration only) ↔ R Stress-induced apoptosis (select models) High free DHA can perturb ER Ca²⁺ handling; typically supra-physiologic exposure.
8 Clinical Translation Constraint — — — Adjunct potential In-vitro dosing often exceeds systemic free DHA; best studied as chemo-sensitizing adjunct rather than monotherapy.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr


Docosahexaenoic Acid (DHA) — Alzheimer’s Disease–Relevant Axes

Rank Pathway / Axis Cells (neurons/glia) TSF Primary Effect Notes / Interpretation
1 Membrane fluidity / synaptic integrity ↑ G Synaptic stabilization DHA major neuronal phospholipid; supports dendritic spine density and neurotransmission.
2 Neuroinflammation resolution ↓ (pro-resolving) R→G Resolvins / protectins Promotes resolution rather than suppression of inflammation; relevant in microglial activation.
3 Mitochondrial efficiency ↑ (stabilizing) R→G Bioenergetic support Improves membrane dynamics of mitochondria; may enhance ATP coupling (model-dependent).
4 Aβ processing / amyloid burden ↓ (preclinical) G Modulates APP cleavage Animal/cell data supportive; human trials mixed, stronger in early/MCI stages.
5 BDNF / neuroplasticity ↑ (model-dependent) G Neurotrophic support Reported increase in BDNF signaling in experimental models.
6 Clinical Translation Constraint — — Stage-dependent benefit MCI/early AD may benefit; established AD shows limited cognitive reversal in RCTs; incorporation requires sustained intake.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr
LDH, Lactate Dehydrogenase: Click to Expand ⟱
Source:
Type:
LDH is a general term that refers to the enzyme that catalyzes the interconversion of lactate and pyruvate. LDH is a tetrameric enzyme, meaning it is composed of four subunits.
LDH refers to the enzyme as a whole, while LDHA specifically refers to the M subunit. Elevated LDHA levels are often associated with poor prognosis and aggressive tumor behavior, similar to elevated LDH levels.
leakage of LDH is a well-known indicator of cell membrane integrity and cell viability [35]. LDH leakage results from the breakdown of the plasma membrane and alterations in membrane permeability, and is widely used as a cytotoxicity endpoint.

However, it's worth noting that some studies have shown that LDHA is a more specific and sensitive biomarker for cancer than total LDH, as it is more closely associated with the Warburg effect and cancer metabolism.

Dysregulated LDH activity contributes significantly to cancer development, promoting the Warburg effect (Chen et al., 2007), which involves increased glucose uptake and lactate production, even in the presence of oxygen, to meet the energy demands of rapidly proliferating cancer cells (Warburg and Minami, 1923; Dai et al., 2016b). LDHA overexpression favors pyruvate to lactate conversion, leading to tumor microenvironment acidification and aiding cancer progression and metastasis.

Inhibitors:
Flavonoids, a group of polyphenols abundant in fruit, vegetables, and medicinal plants, function as LDH inhibitors.
LDH is used as a clinical biomarker for Synthetic liver function, nutrition

Tier A — Direct LDH Enzyme Inhibitors (Validated Catalytic Inhibition)

Rank Compound Type LDH Target Potency Level Primary Effect Notes
1 NCI-006 Research drug LDHA / LDHB High (in vivo active) Potent glycolysis suppression Modern benchmark LDH inhibitor used in metabolic oncology models.
2 (R)-GNE-140 Research drug LDHA (±LDHB) High (nM range reported) Lactate production ↓ Widely used experimental LDH inhibitor.
3 FX11 Research drug LDHA High (μM range) Metabolic crisis in LDHA-dependent tumors Classic LDHA inhibitor; often increases ROS secondary to metabolic stress.
4 Oxamate Tool compound LDH (pyruvate-competitive) Moderate (mM cellular use) Reduces lactate flux Classical LDH inhibitor; requires high concentrations in cells.
5 Gossypol Natural product derivative LDHA Moderate–High Glycolysis inhibition Also has other targets; safety considerations apply.
6 Galloflavin Natural compound LDH isoforms Moderate Lactate production ↓ One of the better-supported “natural-like” LDH inhibitors.

Tier B — Indirect LDH-Axis Modulators (Glycolysis / Lactate Reduction Without Confirmed Direct Catalytic Inhibition)

Rank Compound Mechanism Type LDH Claim Type Primary Axis Notes / Caution
1 Lonidamine MCT/MPC modulation Lactate axis inhibition Metabolic transport blockade Better classified as lactate/pyruvate transport modulator.
2 Stiripentol Repurposed drug LDH pathway modulation Metabolic axis modulation Emerging oncology interest; primarily neurological drug.
3 Quercetin Flavonoid Reported LDH inhibition (mixed evidence) NF-κB / PI3K modulation Often LDH-release confusion; direct enzymatic proof limited.
4 Ursolic acid Triterpenoid Reported LDH interaction Warburg modulation More credible as metabolic signaling modulator.
5 Fisetin Flavonoid Docking / indirect reports Apoptosis / survival signaling Enzyme inhibition not well validated.
6 Resveratrol Polyphenol Indirect glycolysis suppression AMPK / HIF-1α modulation Reduces lactate via upstream signaling.
7 Curcumin Polyphenol Indirect LDH expression modulation Inflammation + metabolic signaling Bioavailability limits translational strength.
8 Berberine Alkaloid Indirect metabolic modulation AMPK activation Closer to metformin-like metabolic pressure.
9 Honokiol Lignan Indirect glycolysis effects Survival pathway suppression Not validated as catalytic LDH inhibitor.
10 Silibinin Flavonolignan Mixed / indirect reports Inflammation + metabolic axis Often misclassified as LDH inhibitor.
11 Kaempferol Flavonoid Often LDH-release marker confusion Glucose transport / signaling Do not list as direct LDH inhibitor without enzyme data.
12 Oleanolic acid / Limonin / Allicin / Taurine Natural compounds Weak / indirect evidence General metabolic modulation Should not be categorized as true LDH inhibitors.

Tier A = Direct catalytic LDH inhibition (enzyme-level validation).
Tier B = Indirect lactate reduction or glycolytic modulation without strong catalytic inhibition evidence.
Important: LDH release assays (cell damage marker) are not proof of LDH enzymatic inhibition.



Scientific Papers found: Click to Expand⟱
951- DHA,    Docosahexaenoic Acid Attenuates Breast Cancer Cell Metabolism and the Warburg Phenotype by Targeting Bioenergetic Function
- in-vitro, BC, BT474 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
Hif1a↓, GLUT1↓, LDH↓, GlucoseCon↓, lactateProd↓, ATP↓, p‑AMPK↑, ECAR↓, OCR↓, *toxicity↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis ⓘ

p‑AMPK↑, 1,   ECAR↓, 1,   GlucoseCon↓, 1,   lactateProd↓, 1,   LDH↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,  

Clinical Biomarkers ⓘ

LDH↓, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: LDH, Lactate Dehydrogenase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:70  Target#:906  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page